AGIO insider sells shares

What happened: On April 1, 2026, Maze Therapeutics' Chief Medical Officer Harold Bernstein sold all his direct holdings of 15,000 shares, valued at around $442,000, at approximately $29.46 per share. This sale represented 100% of his direct holdings, reducing his ownership to zero. Additionally, on March 5, 2026, an insider at Agios Pharmaceuticals sold 2,959 shares worth around $82,000, representing 36.5% of their direct holdings.

Market impact: These insider sales, coupled with a price target reduction by BofA analyst Alec Stranahan due to increased regulatory risk and competition from Novo Nordisk's etavopivat, have negatively impacted Agios Pharmaceuticals' stock price. The stock entered oversold territory with an RSI reading of 29.6 on Monday, while the S&P 500 ETF (SPY) maintained a reading of 68.0. Despite these developments, Agios remains on BofA's list of oversold small-cap stocks to buy.

What to watch next: Investors should closely monitor Agios' upcoming pipeline catalysts, particularly the results for tebapivat in 2026. Additionally, the market will be watching Agios' earnings dates and any further regulatory decisions regarding its drugs, especially mitapivat, which faces competition from Novo Nordisk's etavopivat.